Bibliografía del artículo
1. Colao A, Lombardi G. Growth hormone and prolactin excess. Lancet 352:1455-1461, 1998.
2. Wright AD, Hill DM, Lowy C, Fraser TR. Mortality in acromegaly. Q J Med 39:1-16, 1970.
3. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis and management. Endocr Rev 25:102-152, 2004.
4. Bates AS, Van't Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Q J Med 86:293-299, 1993.
5. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol 41:95-102, 1994.
6. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89:667-674, 2004.
7. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85:526-529, 2000.
8. Melmed S, Casanueva FF, Cavagnini F, et al. Guidelines for acromegaly management. J Clin Endocrinol Metab 87:4054-4058, 2002.
9. Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical "cure". Eur J Endocrinol 152:379-387, 2005.
10. Biermasz NR, Pereira AM, Neelis KJ, Roelfsema F, Romijn JA. Role of radiotherapy in the management of acromegaly. Exp Rev Endocrinol Metab 1:449-460, 2006.
11. Landolt AM, Haller D, Lomax N, et al. Stereotactic radiosurgery for recurrent surgically treated acromegaly: Comparison with fractionated radiotherapy. J Neurosurg 88:1002-1008, 1998.
12. Attanasio R, Epaminonda P, Motti E, et al. Gamma-knife radiosurgery in acromegaly: a 4-year-follow-up study. J Clin Endocrinol Metab 88:3105-3112, 2003.
13. Liuzzi A, Chiodini PG, Botalla L, Cremascoli G, Muller EE, Silvestrini F. Decreased plasma growth hormone (GH) levels in acromegalics following CB 154 (2-Br-alpha-ergocryptine) administration. J Clin Endocrinol Metab 38:910-914, 1974.
14. Chiodini PG, Liuzzi A, Botalla L, Oppizzi G, Muller EE, Silvestrini F. Stable reduction of plasma growth hormone (hGH) during the chronic administration of 2-Br-alpha-ergocryptine (CB-154) in acromegalic patients. J Clin Endocrinol Metab; 40:705-708, 1975.
15. Jaffe CA, Barkan AL. Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin NA 21:713-735, 1992.
16. Kleinberg DL, Boyd AE, Wardlaw S, et al. Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone. N Engl J Med 309:704-709, 1983.
17. Chiodini PG, Attanasio R, Cozzi R, et al. CV 205-502 in acromegaly. Acta Endocrinol (Kbh) 128:389-393, 1993.
18. Lombardi G, Colao A, Ferone D, et al. CV 205-502 treatment in therapy-resistant acromegalic patients. Eur J Endocrinol 132:559-564, 1995.
19. Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 83:374-378, 1998.
20. Cozzi R, Attanasio R, Barausse M, et al. Cabergoline in acromegaly: a renewed role for dopamine agonist treatment? Eur J Endocrinol 139:516-521, 1998.
21. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 90:4465-4473, 2005.
22. Vance ML, Harris AG 1991 Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group. Arch Int Med 151:1573-1588.
23. Cozzi R, Attanasio R, Montini M, et al. Four-year treatment with octreotide-LAR in 110 acromegalic patients: the predictive value of short-term results. J Clin Endocrinol Metab 88:3090-3098, 2003.
24. Attanasio R, Baldelli R, Pivonello R, et al. Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. J Clin Endocrinol Metab 88:5258-5265, 2003.
25. Cozzi R, Montini M, Attanasio R, et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to 9 years) prospective study on its efficacy in the control of disease activity and on tumor shrinkage. J Clin Endocrinol Metab 91:1397-1403, 2006.
26. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342:1171-1177, 2000.
27. Lamberts SW, Zweens M, Verschoor L, del Pozo E. A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine and the combination of both drugs. J Clin Endocrinol Metab 63:16-19, 1986.
28. Chiodini PG, Cozzi R, Dallabonzana D, et al. Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine. J Clin Endocrinol Metab 64:447-453, 1987.
29. Fredstorp L, Kutz K, Werner S. Treatment with octreotide and bromocriptine in patients with acromegaly: an open pharmacodynamic interaction study. Clin Endocrinol 41:103-108, 1994.
30. Flogstad AK, Halse J, Grass P, et al. A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly. J Clin Endocrinol Metab 79:461-465, 1994.
31. Marzullo P, Ferone D, Di Somma C, et al. Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. Pituitary 1:115-120, 1999.
32. Selvarajah D, Webster J, Ross R, Newell-Price J. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur J Endocrinol 152:569-574, 2005.
33. Gatta B, Hau DH, Catargi B, Roger P, Tabarin A. Re-evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patients. Clin Endocrinol 63:477-481, 2005.
34. Cozzi R, Attanasio R, Lodrini S, Lasio G. Cabergoline addition to depot somatostatin analogs in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol 61:209-215, 2004.
35. Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 84:2518-2522, 1999.
36. Lamberts SW, Liuzzi A, Chiodini PG, Verde G, Klijn JG, Birkenhager JC. The value of plasma prolactin levels in the prediction of the responsiveness of growth hormone secretion to bromocriptine and TRH in acromegaly. Eur J Clin Invest 12:151-155, 1982.
37. Saveanu A, Lavaque E, Gunz G, et al. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J Clin Endocrinol Metab 87:5545-5552, 2002.